Search results
Key Points. This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
18 lis 2020 · Among users of the LNG-IUD, 297 had breast cancer, and 3373 breast cancers were observed among the controls. The LNG-IUD users had a strongly reduced risk of ovarian and endometrial cancer compared with those who had never used the device, and there was no increased risk of breast cancer.
6 dni temu · A new study has found a link between hormonal intrauterine devices (IUDs) and breast cancer. The research is important, but media reports of a large increase in risk may be causing...
23 wrz 2022 · Overall, 54.2% of patients reported contraceptive use at the time of breast cancer diagnosis, but a significant decrease in use was observed during primary treatment (year 1) and follow-up (year 2).
7 gru 2017 · Our results suggest the rapid disappearance of excess risk of breast cancer after discontinuation of use among women who have used hormonal contraceptives for short periods, whereas the risk...
Our objective was to conduct a systematic review and meta-analysis of the literature on the risk of breast cancer development in women using the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS).
